Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the
development of neutralizing autoantibodies (inhibitors) against coagulation factor VIII (FVIII) …

Acquired hemophilia A (AHA) is a rare bleeding disorder (1.4 per million inhabitants per
year) caused by neutralizing antibodies against factor VIII. Although uncommon, these …

Acquired hemophilia A (AHA) is an inhibitory coagulopathy that represents a rare variant of
hemorrhagic syndromes. We present a case of idiopathic AHA in a 75-year-old male patient …

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by the development of
specific autoantibodies against factor VIII (FVIII). Immunotherapy is a recent therapeutic …

Abstract rFVIIa, a human recombinant activated coagulation factor VII, has been used
worldwide for more than two decades for the treatment of bleeding episodes and prevention …

Background Emicizumab, a bispecific factor VIII mimetic antibody, was approved in 2018 for
bleeding prophylaxis in congenital hemophilia A with or without inhibitors. Since then …

Vaccination against SARS‐CoV2 has been the largest vaccination campaign over the past
two decades. The aim of this study is to qualitatively assess the reported cases of acquired …

Hemophilia A, the most common hereditary disorder, is caused by clotting factor deficiency.
Challenges encountered in the current treatment of hemophilia A [factor VIII (FVIII) …

Background. Acquired hemophilia A (AHA) is a potentially life‐threatening autoimmune
hemostatic disorder where autoantibodies that disrupt the functions of factor VIII (FVIII) are …

Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological
inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events …